Background
==========

Levofloxacin covers a broad spectrum of pathogens and is readily prescribed by clinicians. Hepatotoxicity is a known but unusual complication of levofloxacin use. Clinical trial data of over 7000 subjects suggests a remarkably low frequency (0.3%) of associated liver enzyme elevation, and data collected since public debut estimates the rate of hepatotoxicity to be less than 1 per 1 million prescriptions \[[@b1-amjcaserep-19-272],[@b2-amjcaserep-19-272]\]. Some data has even estimated this rate to be less than 1 per 5 million prescriptions \[[@b3-amjcaserep-19-272]\]. In comparison, it has been estimated that upwards of 40 000 Americans experience drug-induced liver injury (DILI) each year, and of those cases, it is posited that nearly 50% are due to antimicrobial therapies \[[@b4-amjcaserep-19-272]\]. Here, we present a rare case of severe transaminitis in a patient taking levofloxacin to treat gram-negative bacillary bacteremia.

Case Report
===========

A young man in his thirties with a history of asthma, meth-amphetamine intravenous drug abuse (IVDA), chronic alcohol abuse, and non-compliant insulin-dependent diabetes mellitus (IDDM) presented to an emergency department with suicidal ideation. Vital signs were stable and upon symptomatic review, the patient reported having body aches, chills, sinus congestion, and rhinorrhea. The patient was noted to have cellulitis of the right forearm, for which cultures were drawn, and he received IV clindamycin. Urine toxicology was negative for any recent illicit drug use, and the acetaminophen level was also normal. Lab test results showed hyperglycemia with borderline diabetic ketoacidosis (DKA). The patient was given IV fluids and IV insulin for treatment of DKA, and blood glucose improved to 180 mg/dL. He was then admitted under the psychiatry service to the behavioral medicine unit (BMU) for medical treatment. Antibiotic therapy was switched from intravenous to oral clindamycin and he was followed by the medicine team while in the BMU. Blood cultures were positive for gram-negative rods. Oral levofloxacin was added to the antibiotic regimen on day 2 of admission, pending type and sensitivity of the culture results. The patient was transferred to the medicine floor for further evaluation and to rule out endocarditis in light of the IVDA. Cultures eventually grew *Brevundimonas diminuta*. The clinical significance of this result was uncertain due to the possibility of contamination. Ultrasound showed thrombophlebitis of the basilic vein and a 2D echocardiogram showed mild thickening of the mitral valve anterior leaflet, with no obvious valvular vegetations. This was discussed with the cardiology team and the findings were not suggestive of endocarditis, so no TEE (transesophageal echocardiogram) was recommended. After evaluation by the infectious disease team, clindamycin was discontinued on day 4 and the patient remained on oral levofloxacin.

Liver enzyme levels measured soon after levofloxacin administration showed significant transaminitis (AST 665 IU/L, ALT 364 IU/L, and ALP 207 IU/L). Levofloxacin was discontinued on day 5 due to concern about drug-induced hepatotoxicity. Transaminases increased to approximately 50 times that of baseline and peaked at AST 1626 IU/L, ALT 1100 IU/L, and ALP 269 IU/L on the next day ([Table 1](#t1-amjcaserep-19-272){ref-type="table"}). Extensive testing was performed, including transglutaminase, ceruloplasmin, alpha fetoprotein, antimitochondrial M2 antibody, ANA, alpha-1 anti-trypsin, and a hepatitis panel, and results were unremarkable. An ultrasound of the abdomen showed a partially contracted gallbladder and the common bile duct was 7 mm, near the upper limit of normal. Fatty infiltration of the liver was noted, compatible with a history of alcohol use. Repeat blood cultures 5 days after admission showed no growth, and thrombophlebitis had improved.

After levofloxacin was discontinued, transaminase levels decreased to AST 305 IU/L, ALT 619 IU/L, and ALP 232 IU/L by day 8. The patient was discharged and arrangements were made to stay at an outpatient facility for detoxification and to ensure transaminases returned to baseline levels ([Figure 1](#f1-amjcaserep-19-272){ref-type="fig"}).

Discussion
==========

Fluoroquinolones such as levofloxacin act principally through the inhibition of bacterial DNA gyrase, resulting in DNA strand breakage and consequent genomic damage. Although they do not target mammalian isoforms of nucleic DNA gyrase, fluoroquinolone antibiotics have been shown to damage and deplete mitochondrial DNA (mtDNA) in mammalian cells \[[@b5-amjcaserep-19-272]\]. In one study, ciprofloxacin was found to cause a loss of mtDNA, resulting in decreased ATP production and a subsequent arrest in cell division and growth \[[@b6-amjcaserep-19-272]\]. Another study of ciprofloxacin found site-specific mtDNA strand breaks, suggesting damage was due to the inhibition of DNA gyrase \[[@b7-amjcaserep-19-272]\]. Fluoroquinolone antibiotics at clinically relevant levels have also been shown to cause mitochondrial dysfunction through the production of reactive oxygen species \[[@b8-amjcaserep-19-272],[@b9-amjcaserep-19-272]\]. Although the precise mechanism of levofloxacin-induced hepatotoxicity remains unknown, pre-existing hepatic mitochondrial damage in our patient from chronic alcohol abuse, methamphetamine IVDA, and non-compliant IDDM may have decreased the ability of hepatocytes to utilize ATP and initiate cellular repair. Mitochondrial damage as a causative agent in extensive hepatic injury has also been described in hepatitis and cirrhosis \[[@b10-amjcaserep-19-272],[@b11-amjcaserep-19-272]\]. Processes such as these predispose hepatocytes to acute toxicity. The addition of levofloxacin may have further damaged the remaining mtDNA and prevented hepatocellular repair mechanisms from offsetting cellular injury, ultimately leading to rapid and acute liver toxicity. To elucidate the true pathogenesis of levofloxacin-induced hepatotoxicity, further investigation is required.

Fluoroquinolones have been previously linked to hepatotoxicity. A retrospective case-control study of 7862 patients without a history of prior liver disease found a significant association between treatment with fluoroquinolones and an increased risk of hepatotoxicity, most notably with ciprofloxacin and moxifloxacin usage \[[@b12-amjcaserep-19-272]\]. A retrospective population-based study of 746 subjects also identified an increased risk of acquiring hepatotoxicity in older patients who had recently been prescribed either levofloxacin or moxifloxacin \[[@b13-amjcaserep-19-272]\]. A review of 12 patients who experienced hepatotoxicity related to fluoroquinolones found similar features in cases presenting after ciprofloxacin, moxifloxacin, levofloxacin, and gatifloxacin administration, including a short latency period (2--9 days) and abrupt onset of injury with rapid recovery following discontinuation \[[@b14-amjcaserep-19-272]\]. These predominant features mirror the case presented here. In a case report of hepatotoxicity in a hemodialysis patient, after resolution of liver enzyme elevation following levofloxacin discontinuation, successive treatment with ciprofloxacin prompted a recurrent episode of transaminitis \[[@b15-amjcaserep-19-272]\]. Similar presentations across a spectrum of individual cases indicates a probable class effect in certain patients who have fluoroquinolone-induced hepatotoxicity. Therefore, the administration of a divergent fluoroquinolone antibiotic following transaminitis attributed to a single-class agent should generally be avoided. While data on levofloxacin gathered from clinical trials and post-marketing surveillance have demonstrated a largely consistent hepatic risk profile, fulminant liver injury with death shortly thereafter has occurred in several reported cases of levofloxacin-induced hepatotoxicity \[[@b16-amjcaserep-19-272]--[@b18-amjcaserep-19-272]\]. Hepatotoxicity precipitated by fluoroquinolone antibiotics is atypical, but characteristic liver injury in identifiable cases is paroxysmal and severe.

Although normal liver enzyme levels vary among laboratories, generally acceptable ranges for both AST and ALT fall within 10--50 IU/L, while ALP ranges are normally set within 20--140 IU/L. Our laboratory reference ranges are AST 13--39 U/L, ALT 7--52 IU/L, and ALP 34--104 IU/L. In the present case, AST and ALT levels increased to nearly 50 times the baseline level within 72 h, with a noticeably higher increase in AST, a scenario consistent with drug-induced toxicity. Toxic injury, ischemic injury, and acute viral hepatitis are most commonly associated with aminotransferase deviations greater than 10 times the upper limit of normal (ULN). Aminotransferase levels greater than 75×ULN indicate ischemic or toxic injury in more than 90% of cases \[[@b19-amjcaserep-19-272]\]. In our case, hepatitis panel results were negative. Although this patient did not exhibit aminotransferase levels over 75×ULN, the toxic agent was removed early enough to prevent a transient increase of this magnitude. Hy's law is a simple algorithm used by the US Food and Drug Administration (FDA) to assess hepatic safety in clinical drug trials, and has 3 main components: (1) AST or ALT elevation \>3×ULN; (2) total bilirubin (TBL) elevation \>2×ULN; and (3) absence of initial findings of cholestasis (i.e., ALP elevation \<2×ULN) \[[@b20-amjcaserep-19-272]\]. FDA guidance states that any 2 cases meeting these parameters during a clinical trial is "highly predictive that the drug has the potential to cause severe drug-induced liver injury when given to a patient population" \[[@b20-amjcaserep-19-272]\]. In 3 separate studies encompassing over 1500 patients, approximately 10% of patients who met these 3 criteria experienced liver failure culminating in either transplantation or mortality \[[@b21-amjcaserep-19-272]--[@b23-amjcaserep-19-272]\]. In our case, transaminase elevation was far above 3×ULN, TBL elevation was 0.7×ULN, and ALP elevation was 2.6×ULN. Although TBL elevation did not meet Hy's law criteria in our case, the patient presented with a TBL at the lower end of the reference range, which increased to double the baseline measurements soon after levofloxacin administration and was trending upward. Had levofloxacin therapy not been terminated so quickly, additional toxicity may have quickly increased TBL levels to \>2×ULN. Furthermore, the patient in this case did not progress to liver failure. Hy's law criteria also requires ALP elevation to be \<2×ULN in order to exclude cholestasis as an etiology. In our case, ALP elevation was 2.6 × ULN. The patient presented with a high baseline ALP, which never fell below the ULN throughout his stay. In comparison to peak serum ALP, the lowest measured ALP increased by a factor of only 2.08. Additionally, cholestatic injury usually presents as a disproportionate elevation in ALP in comparison to serum aminotransferases \[[@b24-amjcaserep-19-272]\]. Data from a study of over 750 patients with drug-induced liver injury suggest that the risk of developing acute liver failure in subjects with ALP elevation \>2×ULN is equal to that of subjects who meet Hy's law criteria \[[@b25-amjcaserep-19-272]\]. If true, further studies could make the third criterion of Hy's law subsidiary in the determination of the capacity of an agent to produce severe liver injury.

Drug-induced liver injury is a diagnosis of exclusion. There are 3 fundamental elements used to make the diagnosis: (1) drug exposure preceding the onset of liver injury; (2) exclusion of underlying liver disease as a cause; and (3) discontinuation of the drug, leading to improvement in the liver injury \[[@b26-amjcaserep-19-272]\]. Clindamycin discontinuation and levofloxacin administration took place prior to the observed liver enzyme elevations. Despite a patient history of IV drug abuse, urine toxicology on admission was negative for any illicit drugs, substantially lowering the probability that methamphetamine abuse produced the slightly elevated liver enzyme levels seen on admission, and later prompted further progression to acute liver injury. DKA resolved approximately 36 h prior to levofloxacin administration, and blood glucose levels remained stable until discharge. Moreover, transaminitis did not begin to evolve until 2 days after admission. These observations indicate that DKA was not responsible for the considerable elevation in serum transaminase levels. It is far more likely that pre-existing liver damage constrained hepatic function to a threshold at which additional noxious insult from levofloxacin administration resulted in abrupt hepatocellular failure. Once levofloxacin was discontinued, transaminase levels began to rapidly decrease, supporting levofloxacin as the cause of hepatotoxicity.

Conclusions
===========

Clinicians should remain mindful that levofloxacin can induce hepatotoxicity in rare cases. Patients with pre-existing liver damage may be especially susceptible, and levofloxacin may not be the best antibiotic to prescribe in questionable cases. Although rare, current recommendations for levofloxacin mandate therapy be discontinued immediately if a patient develops signs and symptoms of hepatitis. Likewise, if transaminase levels begin to increase rapidly in a patient receiving levofloxacin for antimicrobial therapy, we recommend prompt removal because it is most likely the offending agent. In patients presenting with acute liver injury who have recently taken levofloxacin, it would be wise for clinicians to remain cognizant to the possibility of levofloxacin-induced hepatotoxicity.
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###### 

Hepatic function panel results before and after levofloxacin administration.

  Test                                     Unit    Reference                                 Days after admission                                                                
  ---------------------------------------- ------- ----------------------------------------- ---------------------- ---- ---- --------- --------- --------- ---------- --------- ---------
  Albumin                                  mg/dL   3.5--5.7                                  3.9                    --   --   **3.3**   **3.3**   3.8       3.7        **3.4**   3.7
  Protein, Total                           mg/dL   6.0--8.9                                  6.7                    --   --   **5.4**   **5.7**   6.4       6.4        **5.7**   6.0
  Alkaline Phos.                           IU/L    34--104                                   **175**                --   --   **129**   **167**   **207**   **269**    **233**   **232**
  ALT                                      IU/L    7--52                                     24                     --   --   **76**    **171**   **364**   **1100**   **773**   **619**
  AST                                      IU/L    13--39                                    **59**                 --   --   **188**   **314**   **665**   **1626**   **632**   **305**
  Bilirubin, Total                         mg/dL   0.3--1.0                                  0.5                    --   --   0.3       0.3       0.4       0.6        0.7       0.6
  Bilirubin, Direct                        mg/dL   0.0--0.2                                  --                     --   --   0.1       0.1       0.1       0.2        0.2       0.2
  Bilirubin, Indirect                      mg/dL   0.0--0.8                                  --                     --   --   0.2       0.2       0.3       0.4        0.5       0.4
  Antibiotics administered                                                                                                                                                       
                                                   **Levofloxacin** Administered days 2--5                                                                                       
  **Clindamycin** Administered days 0--4                                                                                                                                         

ALT -- alanine transaminase; AST -- aspartate transaminase (AST).
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